What is Barrington Research’s Forecast for MMSI Q1 Earnings?

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Analysts at Barrington Research cut their Q1 2025 earnings estimates for Merit Medical Systems in a research report issued on Wednesday, February 26th. Barrington Research analyst M. Petusky now anticipates that the medical instruments supplier will post earnings of $0.76 per share for the quarter, down from their prior estimate of $0.88. Barrington Research currently has a “Outperform” rating and a $111.00 target price on the stock. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.37 per share. Barrington Research also issued estimates for Merit Medical Systems’ Q2 2025 earnings at $1.03 EPS, Q4 2025 earnings at $0.98 EPS, Q1 2026 earnings at $0.86 EPS, Q2 2026 earnings at $1.12 EPS, Q3 2026 earnings at $0.98 EPS, Q4 2026 earnings at $1.04 EPS and FY2027 earnings at $4.35 EPS.

Other equities research analysts also recently issued reports about the company. Canaccord Genuity Group dropped their price objective on Merit Medical Systems from $128.00 to $127.00 and set a “buy” rating on the stock in a report on Wednesday. Piper Sandler reissued an “overweight” rating and set a $116.00 price objective (up from $114.00) on shares of Merit Medical Systems in a report on Wednesday, January 29th. Wells Fargo & Company reduced their price target on shares of Merit Medical Systems from $120.00 to $117.00 and set an “overweight” rating on the stock in a research report on Wednesday. Robert W. Baird upped their price objective on Merit Medical Systems from $107.00 to $109.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Finally, Raymond James upped their price target on Merit Medical Systems from $105.00 to $110.00 and gave the company an “outperform” rating in a research report on Tuesday, December 31st. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $108.40.

Merit Medical Systems Trading Down 1.9 %

NASDAQ:MMSI opened at $98.52 on Friday. The stock has a market cap of $5.74 billion, a price-to-earnings ratio of 48.29, a price-to-earnings-growth ratio of 2.34 and a beta of 0.87. Merit Medical Systems has a one year low of $70.70 and a one year high of $111.45. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36. The business’s 50-day simple moving average is $102.83 and its 200 day simple moving average is $99.88.

Institutional Trading of Merit Medical Systems

Several large investors have recently modified their holdings of MMSI. NewSquare Capital LLC acquired a new position in Merit Medical Systems during the 4th quarter valued at $32,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Merit Medical Systems in the 4th quarter valued at $52,000. Federated Hermes Inc. raised its stake in Merit Medical Systems by 139.1% during the fourth quarter. Federated Hermes Inc. now owns 655 shares of the medical instruments supplier’s stock worth $63,000 after acquiring an additional 381 shares in the last quarter. Group One Trading LLC bought a new stake in shares of Merit Medical Systems in the 4th quarter worth about $77,000. Finally, Farther Finance Advisors LLC increased its position in shares of Merit Medical Systems by 32.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,056 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 260 shares in the last quarter. 99.66% of the stock is owned by institutional investors.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.